Fosaprepitant

Fosaprepitant
Clinical data
Trade names	Emend, Ivemend
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a604003
License data	EU EMA: by INN; US DailyMed: Fosaprepitant; US FDA: Fosaprepitant;
Pregnancy; category	AU: B2;
Routes of; administration	Intravenous
ATC code	A04AD12 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Elimination half-life	9 to 13 hours (aprepitant)
Identifiers
	IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid;
CAS Number	172673-20-0 ; 265121-04-8 (dimeglumine);
PubChem CID	219090;
IUPHAR/BPS	7623;
DrugBank	DB06717 ;
ChemSpider	189912 ;
UNII	6L8OF9XRDC;
KEGG	D06597 ;
ChEBI	CHEBI:64321 ;
ChEMBL	ChEMBL1199324 ;
CompTox Dashboard (EPA)	DTXSID801021651 ;
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.414 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F;
	InChI InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 ; Key:BARDROPHSZEBKC-OITMNORJSA-N ;
	(what is this?) (verify)

Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, and in the European Union in January 2008.